Balancing Regulation Against Access to Innovative Pharmaceuticals

Slides:

Advertisements

Similar presentations

Consultative expert working group - proposals Barcelona

Advertisements

1 Public Economics South African research topics Andrew Donaldson National Treasury August 2009.

Collaboration in the Life Sciences November 2011.

Developing Infrastructure Projects. Contents InfraCo Infrastructure Project Development InfraCo’s Role How InfraCo Operates InfraCo in Indonesia.

Patrick Vallance Head of Drug Discovery GlaxoSmithKline

Pharmaceuticals and Global Health: Successes, Challenges and Outlook 19. July 2013, University of Sussex Thomas B. Cueni, Secretary General Interpharma.

H AGUE AND MADRID SYSTEMS Moses Moeletsi Chief Director: Policy and Legislation 11 August 2004.

Workshop ”InDeCS-H: Development of Healthcare Biotechnology SMEs“ 10th September 2009 Budapest Strategy for Hungarian pharmaceutical and biotechnology.

National University of Singapore Department of Pharmacy 21 Nov 2006 KPP Prasad, Ph.D. Quality Operations Director Pfizer Global Manufacturing The Pharmaceutical.

2014. Diamond Members  Alexion  Bristol Myers Squibb  Cardinal Health  Eisai, Inc.  Foundation Medicine  Genomic Health  McKesson  MedImmune.

Pharmaceuticals before and after TRIPS Sudip Chaudhuri Professor of Economics Indian Institute of Management Calcutta BRICS Workshop, Aalborg February,

Pharmaceutical Industry and Boehringer Ingelheim Paul Fonteyne Executive Vice President Head of Marketing & Sales, Prescription Medicines Pharmaceutical.

Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest

Slide 14.1 Cooper et al: Tourism: Principles and Practice, 3e Pearson Education Limited 2005, © retained by authors Chapter 14 Public Sector and Policy.

Chapter 14 Public Sector and Policy

Association of Pharmaceutical Companies Representatives in Georgia APCRG, WASHINGTON DC, February

U.S. Diabetes Therapies and Complications Markets “The growing demand and the introduction of technologically advanced products is likely to transform.

STRATEGIC MANAGEMENT 1 Irina Raynaud Pierre Jean Tessier Nicolas Cabrit Clément Tumoine.

1 UNWANTED/WASTE PHARMACEUTICALS NATIONAL DIALOGUE June 19-20, 2008 Sacramento, CA Post-Consumer Pharmaceutical Stewardship Association.

Options for national/regional production of generic medicines Wilbert Bannenberg, MD MPH Lesotho TRIPS workshop 14 Aug 2014.

QUALITY REPRODUCTIVE HEALTH SUPPLIES Dr Hans V. Hogerzeil Director Essential Medicines & Pharmaceutical Policies.

The Medicines Patent Pool Ellen ‘t Hoen UNITAID Consultative Forum Geneva, 4-5 October 2011.

Creating sustainable value PRESENTATION TO THE HONORABLE MEMBERS OF THE HEALTH PORTFOLIO COMMITTEE OF PARLIAMENT ON THE OCCASION OF THE PUBLIC HEARINGS.

The Pharma Sector: IP Rights and Competition Policy Ninette Dodoo Clifford Chance LLP UOHS Conference, 11 November 2009.

Department of Trade and Industry DRIVING COMPETITIVENESS: TOWARDS A NEW INTEGRATED INDUSTRIAL STRATEGY FOR SUSTAINABLE EMPLOYMENT AND GROWTH Dr David Kaplan.

Medicines and Related Substances Amendment Bill 2008 Presented by: Abeda Williams 5 August 2008 Pharmaceutical Industry Association of South Africa.

National IPR Policy : Takeaways for Pharma & Tech Industry

Medicines and Related Substances Amendment Bill 2008 Pharmaceutical Task Group: Industry Marketing Code Steering Committee Presented by: Maureen Kirkman.

1 Key issues emerging from the Trade Workshop held on 1 August 2013 Presentation to the Portfolio Committee on Trade and Industry – 10 October 2013 Ms.

Hajar Sabuur Johnson & Johnson Worldwide Information Security June 16, 2005

Issue: High Spending, Low Results. Goals: Increased Efficiency Improve quality and delivery of health care services provided. Improve the cost effectiveness.

© Copyright 2002 Frost & Sullivan. All Rights Reserved. U.S. Lipid Regulators Markets New Clinical Trials Should Spark Interest in Lipid Regulators "A.

United States Parkinson's Disease Drug Market 2016:Industry Trends and Analysis

© Copyright 2004 Frost & Sullivan. All Rights Reserved. The European Active Pharmaceutical Ingredients Market Study and Outsourcing Trends Healthcare Group.

Global Active Pharmaceutical Ingredients Market 2017 Analysis, Segmentation, Competitors Analysis, Trends and Forecast by 2022 Phone No.: +1 (214)

Global Antiviral Drugs Market Primary Research, Risk Analysis, Product Research, Trends and Forecast by 2022 Phone No.: +1 (214) id:

Global Antithrombotic Drugs Market Primary Research, Risk Analysis, Product Research, Trends and Forecast by 2022 Phone No.: +1 (214) id:

Global Orphan Drug Market 2017 Analysis, Segmentation, Competitors Analysis, Trends and Forecast by 2022 Phone No.: +1 (214) id:

© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.

Prof. Frederick Abbott UNDP Consultant

© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 Antidiabetics Market to surpass.

THE REAL PARTNER FOR BUSINESS DEVELOPMENT

The pharmaceutical sector in the South African economy

Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest Pharmaceuticals.

Health Technology Assessment

Pharmaceutical Industry Funding Challenges

Intellectual Property Protection and Access to Medicines

PATENTS, TRIPS, FLEXIBILITIES & ACCESS TO MEDICINES

© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 Drug Discovery Informatics.

1ST International High Level Multi-Stakeholders Meeting on Promoting Pharmaceutical Sector Investments in the East African Community (EAC) Region NAIROBI.

THE SELF MEDICATION MANUFACTURERS ASSOCIATION OF SOUTH AFRICA (SMASA)

Antidiabetics Market to grow at 10.5% CAGR from 2017 to 2024

Pharmacovigilance Market to grow at 10% CAGR from 2017 to 2024

Stefan Gijssels, Janssen Pharmaceutica

South Africa Pharmacy Landscape

HIV Drugs Market HIV Drug Market to Reach $26,458 Million, Globally by 2022.

Next-Generation Antibody Therapeutics Market to Witness 44% CAGR during 2015 – 2020.

Nikolai Khaltaev GARD Meeting ERS Congress 3 September, Munich

GENERICS - BRIDGING THE GAP Or BALANCING COST AND ACCESS

An Industry Perspective Nicole Denjoy COCIR Secretary General

Main findings and recommendations from the UNIDO study on the pharmaceutical sector in Zimbabwe Domestication of TRIPs Flexibilities in National IP Legislation.

Harmonization for Patient Centered Universal Health Coverage

Board of Healthcare Funders

ENFORCEMENT AND EXEMPTIONS

Developing cross border capacity development opportunities

An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,

An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,

Active Pharmaceutical Ingredients Market Industry Insights, Growth, Segmentation and Forecasts to 2023 PREPARED BY Market Research Future (Part of Wantstats.

Approach: The Cuban Regulatory Strategy

Multi-Stakeholder Collaboration in Support of Local Production of Pharmaceuticals (LPP) Mr. Godfrey Keele, MPharm (UNIDO) HRDC Summit, 29 March 2016,

Presentation transcript:

Balancing Regulation Against Access to Innovative Pharmaceuticals Vicki Ehrich Chief Operating Officer PIASA 25 July 2007

Benefits of local industry investment and presence Registration and ‘early’ launch of new medicines Local investment in education and training Local investment in clinical research Industry investment in therapeutic areas Local supply to State Sector Skills and technology transfer Pipeline for generic medicines

Attracting Pharmaceutical Investment Financial Incentives Stimulation of Innovation Secure IP Framework Efficient regulatory framework Large volume / funded market Access to high level skills pool

IP Framework Bolar provision Data protection Compulsory licensing/parallel imports Voluntary licensing

Large volume / funded market ‹ 1% world market No developed regional market No regulatory harmonization Stagnant private market Low value government market Little access to donor demand Global competitiveness? Export incentives?

Members of PIASA Abbott Laboratories South Africa (Pty) Ltd Adcock Ingram Healthcare (Pty) Ltd Alcon Laboratories (Pty) Ltd Altana Madaus (Pty) Ltd Astra Zeneca Pharmaceuticals (Pty) Ltd Bayer Schering Pharma (Pty) Ltd Boehringer Ingelheim (Pty) Ltd Bristol-Myers Squibb (Pty) Ltd Galderma Laboratories (Pty) Ltd GE Health (Pty) Ltd Genop Healthcare (Pty) Ltd GlaxoSmithKline South Africa (Pty) Ltd iNova Pharmaceuticals (Pty) Ltd Janssen-Cilag (Pty) Ltd Key Oncologics (Pty) Ltd Merck (Pty) Ltd Novo-Nordisk (Pty) Ltd Schering-Plough (Pty) Ltd Sekunjalo Health Care Ltd Servier Laboratories SA Pty) Ltd Solvay Pharma (Pty) Ltd Stiefel Laboratories (Pty) Ltd Tyco Healthcare (Pty) Ltd UCB Pharma South Africa (Pty) Ltd Wyeth South Africa (Pty) Ltd